viewInvitrocue Ltd

Invitrocue leads market with disruptive technology and personalised oncology solutions

Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company's development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours. 
"We've been able to take some of these really innovative, disruptive technologies and apply it to the space of being able to create these micro-tumours," says Fang.
He continues, "That allows us to test the response of these cancer cells against those specific drugs.
"But it's always done individualised - this whole area of personalised oncology is now coming to market."

Quick facts: Invitrocue Ltd

Price: - AUD

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Invitrocue Ltd named herein, including the promotion by the Company of Invitrocue Ltd in any Content on the Site, the Company receives from...


FenixOro Gold continues aggressive drill program at their Abriaqui Project...

FenixOro Gold (CSE: FENX-OTCQB: FDVXF) CEO John Carlesso joined Steve Darling from Proactive to bring details about their drilling program that is ongoing at their gold silver and copper project in Colombia. That project is called Abriaqui and sits along a very mineralized belt. Carlesso...

13 hours, 24 minutes ago

2 min read